Stem cells are harvested from several different body tissues, and the method depends on which type of stem cell is needed. Bone marrow aspiration from the hip, mobilization and collection from circulating blood, extraction from umbilical cord blood at birth, liposuction of fat tissue, and even reprogramming ordinary skin or blood cells in the lab are all established routes. Each method has its own procedure, recovery profile, and set of trade-offs for the donor or patient.
Bone Marrow Aspiration
Bone marrow harvesting is the oldest method in clinical use, with the first bone marrow transplant performed in 1956.1PubMed Central. Stem cells: a comprehensive review of origins and emerging clinical roles in medical practice It remains a common way to obtain blood-forming stem cells for transplant and mesenchymal stem cells for orthopedic and regenerative therapies. The procedure targets the iliac crest, the curved ridge of the hip bone, because it contains a dense pocket of marrow that is relatively easy to reach.2PubMed Central. Bone Marrow Aspirate Concentrate Harvesting and Processing Technique
Under general or regional anesthesia, a physician inserts a specialized needle through the skin and into the bone, then draws marrow into a syringe. Needle gauge and aspiration depth vary by clinical goal. In one study of adults, an 11-gauge needle was inserted to about 7 centimeters, and small volumes of marrow were pulled at multiple depths and angles along the iliac crest to maximize the concentration of stem cells in the sample.3PubMed Central. Bone Marrow Stem Cell Population in Single- and Multiple-Level Aspiration Drawing from several spots rather than one deep pull tends to yield a richer cell population because each new puncture site taps into a fresh pocket of marrow rather than diluting the sample with peripheral blood.
For transplant donors giving a large volume of marrow, the procedure can involve repeated needle insertions on both sides of the pelvis. That is a bigger deal physically. A National Marrow Donor Program trial found that bone marrow donors were more likely to experience moderate-to-severe side effects at one week, and pain that persisted at the one-month mark, compared to donors who gave stem cells through the blood. About 3% of marrow donors still had not fully recovered at 24 weeks.4PubMed Central. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program Pre-donating and later reinfusing a unit of the donor’s own blood has been shown to reduce these complications and speed recovery.5PubMed Central. Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: a CIBMTR analysis
Peripheral Blood Stem Cell Collection
Most stem cells normally stay anchored inside bone marrow. To collect them from the bloodstream instead, doctors first coax them out using medication, a process called mobilization. The standard drug is a growth factor called G-CSF, which stimulates the marrow to overproduce stem cells until they spill into the circulating blood. The donor typically injects G-CSF under the skin for four or five days before collection.
When G-CSF alone does not push enough stem cells into the blood, a second drug called plerixafor can be added. Plerixafor works differently: it blocks the molecular handshake that keeps stem cells tethered to the marrow, effectively loosening their grip and releasing them into the bloodstream.6PubMed Central. Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update 7PubMed Central. Physiology and pharmacology of plerixafor This combination is especially useful for patients who have already received chemotherapy, which can damage the marrow’s ability to mobilize cells on its own.
Once enough stem cells are circulating, the donor or patient is connected to an apheresis machine. Blood is drawn from one arm, spun through the device to separate out the stem-cell-rich fraction, and the remainder is returned through the other arm. The whole session can last several hours, and collection efficiency varies by person. Research modeling the process has found that the sex of the donor is a significant factor influencing how many cells can be collected per liter of blood processed, with female donors tending to yield fewer cells per pass.8Chulalongkorn Medical Journal. The mathematical model predicts peripheral blood CD34+ cell yield and blood volume processing for peripheral blood stem cell apheresis
Umbilical Cord Blood
Cord blood is collected immediately after a baby is born, making it the only stem cell source that involves no procedure on the donor at all. Once the umbilical cord is clamped, a needle is inserted into the cord’s vein and blood drains by gravity into a collection bag. The timing and technique matter for how much blood you get. A clinical trial comparing collection before versus after the placenta is delivered found that both approaches can yield usable samples, provided the cord is clamped about a minute after birth and the collection meets a minimum weight threshold of around 85 grams.9PubMed. Evaluation of ex-utero collection for umbilical cord blood banking: A randomized clinical trial comparing cord blood quality with the in-utero technique
The collection technique itself also affects volume. A study comparing three approaches found significant differences: collecting after the placenta was placed on a flat surface (the “plateau” method) yielded a median of about 70 milliliters, while collecting while the placenta was still inside the uterus yielded about 56 milliliters, and using a funnel setup collected only about 36 milliliters.10PubMed. Comparing the volume of umbilical cord blood collection using different techniques These numbers matter because cord blood units are small to begin with, and a higher volume generally means more total stem cells available for transplant.
Once collected, the cord blood must be processed and frozen for storage. The standard approach uses a cryoprotectant called DMSO to prevent ice crystals from destroying the cells during freezing. Conventional protocols use 10% DMSO, but newer research suggests that lower concentrations, around 5%, combined with additives like trehalose or ascorbic acid, can preserve cell viability just as well or better while reducing the toxicity that DMSO causes when the unit is eventually thawed and infused into a patient.11World Journal of Experimental Biosciences. Integrated Low-DMSO Cryopreservation and Expansion Strategies Enhance Cord Blood CD34⁺ Stem Cell Recovery and Function Interestingly, whether you use a controlled-rate freezer or simply place the unit in a mechanical freezer at the right temperature does not seem to make a significant difference in cell quality after thawing.12Blood. Comparison of Controlled vs Non-Controlled Rate Freezing of Umbilical Cord Blood Units
Adipose Tissue and Liposuction
Fat tissue turns out to be a surprisingly rich source of mesenchymal stem cells. The collection method will sound familiar to anyone who has heard of cosmetic liposuction: a thin cannula is inserted under the skin, typically around the abdomen or thigh, and fat is suctioned out. The resulting lipoaspirate is then processed in the lab, usually with an enzyme called collagenase that breaks down the fat tissue and releases the stem cells from the surrounding scaffold. Protocols exist for processing volumes well over 100 milliliters of lipoaspirate, making it one of the higher-yield sources available.13PubMed. Isolation of Human Adipose-Derived Stem Cells from Lipoaspirates
Compared to bone marrow stem cells from the same donors, fat-derived stem cells grow faster in culture and are more reliable to expand in the lab regardless of the patient’s age or health status.14PubMed Central. Human Bone Marrow versus Adipose-Derived Stem Cells: Influence of Donor Characteristics on Expandability and Implications for Osteogenic Ex Vivo BMP-2 Regional Gene Therapy That practical advantage matters for therapies that need a large number of cells. The trade-off is biological: donor-matched comparisons show that while fat-derived cells are better at proliferating and forming fat tissue, bone marrow cells are significantly better at forming bone and cartilage.15PubMed Central. Adipose-derived and bone marrow mesenchymal stem cells: a donor-matched comparison The choice of source depends heavily on what the cells will be used for.
An important regulatory wrinkle applies here. In many countries, using enzymes to isolate cells from fat tissue is classified as “more than minimal manipulation,” which subjects the product to the same regulatory review as a drug. To sidestep that burden, mechanical methods have been developed that process the tissue without enzymatic digestion, producing a product that stays within the “minimally manipulated” category and can sometimes be used in the same surgical session.16PubMed Central. Intraoperative Strategies for Minimal Manipulation of Autologous Adipose Tissue for Cell- and Tissue-Based Therapies: Concise Review The trade-off is that mechanically processed fat contains a less purified cell population than the enzymatically digested version.
Embryonic Stem Cells and Lab-Made Alternatives
Embryonic stem cells come from the inner cell mass of a blastocyst, the ball of cells that forms a few days after fertilization. Isolating them is a laboratory procedure, not a clinical one performed on a living donor. Traditionally, the inner cell mass was freed using a technique called immunosurgery, which uses antibodies to dissolve the outer cell layer. That approach is slow and introduces animal-derived materials, raising contamination concerns for any future clinical use. Microsurgical alternatives now exist that use fine mechanical tools under a microscope to physically cut away the outer layer and extract the inner mass without animal products.17Cell Research. Efficient isolation inner cell mass from blastocysts by improved microsurgical technique
Because embryonic stem cell derivation destroys the embryo, it remains ethically contentious. That controversy helped drive the development of induced pluripotent stem cells, or iPSCs, which are made by reprogramming ordinary adult cells back into a stem-like state. The original and still most common starting material is fibroblasts from a small skin biopsy. These cells are isolated from the tissue sample and then exposed to a set of key genes that rewind their developmental clock.18PubMed. Method Optimization of Skin Biopsy-Derived Fibroblast Culture for Reprogramming Into Induced Pluripotent Stem Cells The resulting iPSCs behave much like embryonic stem cells, able to become almost any cell type in the body, but they come from the patient’s own tissue.
The field has been expanding the menu of starting materials. Blood cells from a simple draw, cells shed in urine, and even cells from extracted wisdom teeth have all been successfully reprogrammed into iPSCs.19PubMed Central. A Comparative View on Human Somatic Cell Sources for iPSC Generation Each source has its own practical pros and cons. Blood and urine are easier to collect than skin, which requires a biopsy. But the reprogramming efficiency and speed can vary with cell type, so the choice often comes down to what is most practical for a given patient and clinical goal.
Dental Pulp Stem Cells
The soft tissue inside teeth, called dental pulp, contains mesenchymal stem cells that have attracted research interest for bone regeneration and nerve repair. Third molars (wisdom teeth) are the most studied source, since they are routinely extracted and would otherwise be discarded. Once a tooth is removed, the pulp can be accessed either by splitting the tooth open through the crown or by pushing the tissue out through the root end. A randomized comparison of these two approaches found no significant differences in cell viability or the cells’ ability to differentiate into hard tissue.20PubMed. Effect of the pulp harvesting method on the viability of human dental pulp stem cells and their odontogenic differentiation potential
In the lab, the extracted pulp is processed using one of several techniques: digesting it with enzymes to release individual cells, culturing intact pulp pieces and letting cells migrate out on their own, or a combination of both.21PubMed Central. A modified efficient method for dental pulp stem cell isolation The enzyme digestion method tends to yield cells faster, while the outgrowth method is gentler and avoids potential enzyme-related damage. Dental stem cells remain a niche source, but the appeal is clear: they come from tissue that is already being thrown away, and the collection adds no extra burden to the patient beyond the extraction they were already having.
How Do You Know the Cells Are Actually Stem Cells?
Regardless of how stem cells are harvested, confirming their identity is a critical step that is easy to overlook in popular discussions. The standard method uses a technology called flow cytometry to check which surface markers the cells carry. For mesenchymal stem cells, the expected profile includes positive expression of markers like CD44, CD73, CD90, and CD105, and negative expression of markers associated with blood cells, like CD34 and CD45.22PubMed Central. Characterization and Classification of Mesenchymal Stem Cells in Several Species Using Surface Markers for Cell Therapy Purposes
The trouble is that the marker profiles are not always clean-cut. Research comparing stem cells from Wharton’s jelly, adipose tissue, bone marrow, and placental tissue with ordinary fibroblasts found that many of the commonly used markers were expressed at virtually identical levels in all cell types. Statistically significant differences showed up only for a subset of markers, including CD105, CD106, and CD146.23Archives of Medical Science. Flow cytometric characterization of cell surface markers to differentiate between fibroblasts and mesenchymal stem cells of different origin This means a lab relying only on the basic marker panel could mistake fibroblasts for stem cells, or vice versa. The practical implication for patients considering stem cell therapies: ask what quality-control testing the provider uses, because simply calling something a “stem cell product” does not guarantee the cells in the vial are what the label says.
Long-Term Safety for Donors
A persistent worry, especially for people donating peripheral blood stem cells, is whether the mobilization drugs could increase the risk of cancer years later. The concern is understandable: G-CSF forces the bone marrow into overdrive, and any drug that stimulates cell growth invites the question of whether it might trigger something malignant.
The best long-term data come from a Swedish registry study that tracked over a thousand healthy peripheral blood stem cell donors for a median of nearly 10 years. The cancer rate among donors was not meaningfully different from that of age- and sex-matched controls from the general population. Even when hematological cancers were looked at specifically, the slightly higher rate seen among donors was not statistically significant.24Bone Marrow Transplantation. Cancer incidence in healthy Swedish peripheral blood stem cell donors A separate study following pediatric donors who received G-CSF found no cases of cancer at a median follow-up of nearly five years, and two pregnancies that occurred after donation resulted in healthy births.25Biology of Blood and Marrow Transplantation. Evaluation of Early and Late Adverse Effects of Peripheral Blood Stem Cell Donation in Healthy Pediatric Donors
These findings are reassuring, though researchers acknowledge that truly rare late effects could take even longer to show up. Registries continue to track donors for this reason. The current evidence, however, does not support the idea that stem cell donation raises cancer risk.
Keeping Cells Alive After Collection
Harvesting stem cells is only half the battle. Getting them to the patient or the lab in good condition requires careful temperature management. For freshly harvested peripheral blood stem cells, research has shown that the best temperature range for overnight storage and transport is between 2 and 8 degrees Celsius. Cells stored at room temperature or higher show a measurable drop in viability.26PubMed. Fresh PBSC harvests, but not BM, show temperature-related loss of CD34 viability during storage and transport Bone marrow samples, interestingly, appear to tolerate temperature variation somewhat better.
For mesenchymal stem cells from other sources, the preservation medium matters as much as the temperature. Synovial stem cells stored in human serum at 4 to 13 degrees Celsius maintained their viability, surface marker expression, and ability to form cartilage, while cells stored in standard saline solutions under the same conditions lost much of their function.27PubMed Central. Complete human serum maintains viability and chondrogenic potential of human synovial stem cells: suitable conditions for transplantation These details rarely make it into patient-facing discussions, but they are one of the reasons that established transplant centers tend to produce better outcomes than smaller clinics: the logistics chain between harvest and use is where a lot of cell quality is won or lost.
Organoids and the Frontier of Stem Cell Sourcing
A newer dimension of the field does not involve harvesting stem cells from the body at all. Instead, researchers grow pluripotent stem cells in the lab and coax them into forming tiny, simplified versions of organs called organoids. These three-dimensional structures can mimic features of the brain, gut, kidney, or liver, and they serve primarily as research tools for studying disease and testing drugs rather than as direct therapies. To study specific cell types within these organoids, researchers use fluorescence-based sorting to separate the particular populations they need from the heterogeneous mix of cells the organoid produces.28PubMed Central. FACS-Mediated Isolation of Neuronal Cell Populations From Virus-Infected Human Embryonic Stem Cell-Derived Cerebral Organoid Cultures Organoid technology is still largely a research platform, but it represents a direction where the stem cell “harvest” happens entirely in a dish, with no donor and no procedure.